Lindsay M. Avery

403 total citations
23 papers, 307 citations indexed

About

Lindsay M. Avery is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Lindsay M. Avery has authored 23 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pharmacology, 18 papers in Molecular Medicine and 7 papers in Epidemiology. Recurrent topics in Lindsay M. Avery's work include Antibiotics Pharmacokinetics and Efficacy (21 papers), Antibiotic Resistance in Bacteria (18 papers) and Antibiotic Use and Resistance (7 papers). Lindsay M. Avery is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (21 papers), Antibiotic Resistance in Bacteria (18 papers) and Antibiotic Use and Resistance (7 papers). Lindsay M. Avery collaborates with scholars based in United States, Switzerland and Taiwan. Lindsay M. Avery's co-authors include David P. Nicolau, Kamilia Abdelraouf, Joseph L. Kuti, Christina Sutherland, Safa S. Almarzoky Abuhussain, Tomefa E. Asempa, James M. Kidd, Maja Weisser, Adrian Egli and Samuel L Aitken and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Lindsay M. Avery

22 papers receiving 301 citations

Peers

Countries citing papers authored by Lindsay M. Avery

Since Specialization

Citations

This map shows the geographic impact of Lindsay M. Avery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsay M. Avery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsay M. Avery more than expected).

Fields of papers citing papers by Lindsay M. Avery

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsay M. Avery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsay M. Avery. The network helps show where Lindsay M. Avery may publish in the future.

Co-authorship network of co-authors of Lindsay M. Avery

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsay M. Avery. A scholar is included among the top collaborators of Lindsay M. Avery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsay M. Avery. Lindsay M. Avery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model 2025 ·Antimicrobial Agents and Chemotherapy ·Lindsay M. Avery, (unknown), Fan Yi, Greg Moeck, Tsuyoshi Uehara, Daniel C. Pevear	0
2	590. Activities of Cefepime-Taniborbactam and Ceftazidime-Avibactam against Cefepime-Resistant Respiratory Gram-Negative Pathogens in a Hollow Fiber Infection Model 2022 ·Open Forum Infectious Diseases ·Lindsay M. Avery, (unknown), Fan Yi, (unknown), Greg Moeck, Daniel C. Pevear	2
3	In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination 2022 ·Journal of Antimicrobial Chemotherapy ·Andrew J Fratoni, Lindsay M. Avery, David P. Nicolau, Tomefa E. Asempa	5
4	1263. Assessment of Cefepime (FEP)-Taniborbactam (TAN) Human Exposures to Suppress the Emergence of Resistance among Serine (SBL)- and Metallo-β-Lactamase (MBL)-Producing Gram-Negative Bacteria (GNB) in a Hollow Fiber Infection Model (HFIM) 2020 ·Open Forum Infectious Diseases ·Lindsay M. Avery, (unknown), (unknown), L Xerri, Greg Moeck, Daniel C. Pevear	1
5	Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope 2019 ·International Journal of Antimicrobial Agents ·Lindsay M. Avery, (unknown), David P. Nicolau	11
6	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations 2019 ·International Journal of Antimicrobial Agents ·Ana Motos, Lindsay M. Avery, (unknown), (unknown), Joseph L. Kuti, David P. Nicolau	4
7	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration 2019 ·Clinical Therapeutics ·Lindsay M. Avery, (unknown), Sergio Reyes, David P. Nicolau, Joseph L. Kuti	8
8	In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae 2019 ·Diagnostic Microbiology and Infectious Disease ·Lindsay M. Avery, Christina Sutherland, David P. Nicolau	12
9	Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa 2019 ·Journal of Medical Microbiology ·Lindsay M. Avery, Christina Sutherland, David P. Nicolau	22
10	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia 2019 ·International Journal of Antimicrobial Agents ·Lindsay M. Avery, Joseph L. Kuti, Maja Weisser, Adrian Egli, Michael J. Rybak, Evan J Zasowski, César A. Arias, German Contreras, Pearlie P. Chong, Samuel L Aitken, Adam J. DiPippo, Jann‐Tay Wang, Nicholas Britt, David P. Nicolau	8
11	682. In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model When Administered in Combination with Humanized Exposures of Twice Daily Ceftibuten (CTB) Against Serine β-Lactamase-Producing Enterobacteriaceae (SBL-EB) 2019 ·Open Forum Infectious Diseases ·Lindsay M. Avery, Kamilia Abdelraouf, David P. Nicolau	3
12	Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa 2019 ·Antimicrobial Agents and Chemotherapy ·(unknown), Lindsay M. Avery, David P. Nicolau	15
13	Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope 2018 ·International Journal of Antimicrobial Agents ·Lindsay M. Avery, David P. Nicolau	37
14	Impact of a co-curricular, e-learning activity on pharmacy student knowledge of laboratory values 2018 ·Currents in Pharmacy Teaching and Learning ·(unknown), Erin R. Weeda, Lindsay M. Avery, (unknown), (unknown)	6
15	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration 2018 ·American Journal of Health-System Pharmacy ·Tomefa E. Asempa, Lindsay M. Avery, James M. Kidd, Joseph L. Kuti, David P. Nicolau	17
16	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint 2018 ·Clinical Infectious Diseases ·Lindsay M. Avery, Joseph L. Kuti, Maja Weisser, Adrian Egli, Michael J. Rybak, Evan J Zasowski, César A. Arias, German Contreras, Pearlie P. Chong, Samuel L Aitken, Adam J. DiPippo, Jann‐Tay Wang, Nicholas Britt, David P. Nicolau	43
17	1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model 2018 ·Open Forum Infectious Diseases ·Safa S. Almarzoky Abuhussain, Lindsay M. Avery, Kamilia Abdelraouf, David P. Nicolau	1
18	In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model 2018 ·Antimicrobial Agents and Chemotherapy ·Safa S. Almarzoky Abuhussain, Lindsay M. Avery, Kamilia Abdelraouf, David P. Nicolau	30
19	Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model 2018 ·Antimicrobial Agents and Chemotherapy ·Lindsay M. Avery, Kamilia Abdelraouf, David P. Nicolau	35
20	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration 2017 ·Clinical Therapeutics ·James M. Kidd, Lindsay M. Avery, Tomefa E. Asempa, David P. Nicolau, Joseph L. Kuti	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact